Annals of Surgical Oncology

, Volume 14, Issue 5, pp 1638–1643 | Cite as

Results of 23,810 Cases of Ductal Carcinoma-in-situ

  • William E. SumnerIII
  • Leonidas G. Koniaris
  • Sarah E. Snell
  • Seth Spector
  • Jodeen Powell
  • Eli Avisar
  • Frederick Moffat
  • Alan S. Livingstone
  • Dido Franceschi



Screening mammography has increased the number of patients diagnosed with ductal carcinoma-in-situ (DCIS) in the past 20 years. The Florida Cancer Data System is the largest single source incident cancer registry in the United States. We analyzed this registry to determine the changing incidence and treatment patterns for DCIS.


Patients with DCIS from 1981 to 2001 were identified. Age-adjusted rate, descriptive statistics, and incidence of future DCIS and invasive breast cancer were calculated.


A total of 23,810 DCIS patients were identified. The age-adjusted rate of DCIS has risen from 2.4 to 27.7 per 100,000 women between 1981 and 2001. Median age was 64 years; 85% of patients were white, 6.6% African American, and 7.5% Hispanic. Median tumor size was .9 cm. Forty-seven percent of patients had breast-conserving therapy (BCT). Half of the 53% of patients undergoing mastectomy underwent a modified radical mastectomy. Eight percent received no surgical treatment. Sentinel lymph node biopsy was used in 2.7% of patients who underwent a mastectomy. After BCT, 37.5% received adjuvant radiotherapy, and only 13% were treated with hormonal therapy.


The incidence of DCIS has risen dramatically with the advent of screening mammography. Increasing numbers of these patients are treated with BCT, although a large proportion are still treated with mastectomy, in some cases combined with axillary dissection. Sentinel lymph node biopsy and tamoxifen are important components of therapy, the use of which is slowly increasing in the treatment of DCIS.


DCIS Breast cancer Intraductal carcinoma Mastectomy Breast conservation 


  1. 1.
    Betsill WL Jr, Rosen PP, Lieberman PH, Robbins GF. Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone. JAMA 1978; 239:1863–1867PubMedCrossRefGoogle Scholar
  2. 2.
    Nakhlis F, Morrow M. Ductal carcinoma in situ. Surg Clin North Am 2003; 83:821–839PubMedCrossRefGoogle Scholar
  3. 3.
    Fisher B. From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century. Eur J Cancer 1999; 35:1963–1973PubMedCrossRefGoogle Scholar
  4. 4.
    Carrera C, Payne S. Ductal carcinoma in situ (DCIS) of the breast: the need for psychosocial research. Psychooncology 1999; 8:538–545PubMedCrossRefGoogle Scholar
  5. 5.
    Schootman M, Aft R. Rural-urban differences in radiation therapy for ductal carcinoma-in-situ of the breast. Breast Cancer Res Treat 2001; 68:117–125PubMedCrossRefGoogle Scholar
  6. 6.
    Schootman M, Kinman E, Farria D. Rural-urban differences in ductal carcinoma in situ as a proxy for mammography use over time. J Rural Health 2003; 19:470–476PubMedCrossRefGoogle Scholar
  7. 7.
    Simon MS, Lemanne D, Schwartz AG, Martino S, Swanson GM. Recent trends in the incidence of in situ and invasive breast cancer in the Detroit metropolitan area (1975–1988). Cancer 1993; 71:769–774PubMedCrossRefGoogle Scholar
  8. 8.
    Wu X, Chen VW, Ruiz B, et al. Patterns of treatment for ductal carcinoma in situ of the breast in Louisiana, 1988–1999. J La State Med Soc 2003; 155:206–213PubMedGoogle Scholar
  9. 9.
    Wood WC. The role of clinical trials in changing therapy for ductal carcinoma in situ. Ann Surg Oncol 2004; 11:24S–27SPubMedCrossRefGoogle Scholar
  10. 10.
    Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 1996; 275:913–918PubMedCrossRefGoogle Scholar
  11. 11.
    Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R. Mortality among women with ductal carcinoma in situ of the breast in the Population-Based Surveillance, Epidemiology and End Results Program. Arch Intern Med 2000; 160:953–958PubMedCrossRefGoogle Scholar
  12. 12.
    Collette C. A multidisciplinary approach to breast biopsy. AORN J 1999; 69:810–811PubMedCrossRefGoogle Scholar
  13. 13.
    Bodai BI, Boyd B, Brown L, Wadley H, Zannis VJ, Holzman M. Total cost comparison of 2 biopsy methods for nonpalpable breast lesions. Am J Manag Care 2001; 7:527–538PubMedGoogle Scholar
  14. 14.
    Secker-Walker RH, Vacek PM, Hooper GJ, Plante DA, Detsky AS. Screening for breast cancer: time, travel, and out-of-pocket expenses. J Natl Cancer Inst 1999; 91:702–708PubMedCrossRefGoogle Scholar
  15. 15.
    Liberman L, Feng TL, Dershaw DD, Morris EA, Abramson AF. US-guided core breast biopsy: use and cost-effectiveness. Radiology 1998; 208:717–723PubMedGoogle Scholar
  16. 16.
    Brenner RJ, Sickles EA. Surveillance mammography and stereotactic core breast biopsy for probably benign lesions: a cost comparison analysis. Acad Radiol 1997; 4:419–425PubMedCrossRefGoogle Scholar
  17. 17.
    Kerlikowske K, Barclay J, Grady D, Sickles EA, Ernster V. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst 1997; 89:76–82PubMedGoogle Scholar
  18. 18.
    Cox CE, Nguyen K, Gray RJ, et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg 2001; 67:513–519PubMedGoogle Scholar
  19. 19.
    Dupont EL, Kuhn MA, McCann C, Salud C, Spanton JL, Cox CE. The role of sentinel lymph node biopsy in women undergoing prophylactic mastectomy. Am J Surg 2000; 180:274–277PubMedCrossRefGoogle Scholar
  20. 20.
    Klauber-Demore N, Tan LK, Liberman L, et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion? Ann Surg Oncol 2000; 7:636–642PubMedCrossRefGoogle Scholar
  21. 21.
    Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 2004; 96:443–448PubMedCrossRefGoogle Scholar
  22. 22.
    Fisher B, Costantino J, Redmond C, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993; 328:1581–1586PubMedCrossRefGoogle Scholar
  23. 23.
    Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998; 16:441–452PubMedGoogle Scholar
  24. 24.
    Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 2001; 28:400–418PubMedCrossRefGoogle Scholar
  25. 25.
    Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 2002; 20:4141–4149PubMedCrossRefGoogle Scholar
  26. 26.
    Fisher ER, Sass R, Fisher B, Wickerham L, Paik SM. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 6). I. Intraductal carcinoma (DCIS). Cancer 1986; 57:197–208PubMedGoogle Scholar
  27. 27.
    Fisher ER, Leeming R, Anderson S, Redmond C, Fisher B. Conservative management of intraductal carcinoma (DCIS) of the breast. Collaborating NSABP investigators. J Surg Oncol 1991; 47:139–147Google Scholar
  28. 28.
    Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP). Eight-year update of Protocol B-17: intraductal carcinoma. Cancer 1999; 86:429–438Google Scholar
  29. 29.
    Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995; 345:1154–1157PubMedCrossRefGoogle Scholar
  30. 30.
    Silverstein MJ, Lagios MD, Craig PH, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996; 77:2267–2274PubMedCrossRefGoogle Scholar
  31. 31.
    Silverstein MJ. The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg 2003; 186:337–343PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2007

Authors and Affiliations

  • William E. SumnerIII
    • 1
  • Leonidas G. Koniaris
    • 1
  • Sarah E. Snell
    • 1
  • Seth Spector
    • 1
  • Jodeen Powell
    • 1
  • Eli Avisar
    • 1
  • Frederick Moffat
    • 1
  • Alan S. Livingstone
    • 1
  • Dido Franceschi
    • 1
  1. 1.Division of Surgical OncologyDepartment of Surgery, Sylvester Comprehensive Cancer CenterMiamiFlorida

Personalised recommendations